AstraZeneca has entered an AI-driven research agreement with China's CSPC Pharmaceutical Group, potentially worth up to $5.3 billion, aimed at developing therapies for chronic diseases. This partnership follows previous collaborations and reflects AstraZeneca's strategy to enhance its presence in China's pharmaceutical market.